Roche inks $50M ADC pact with Chinese biotech as field’s flurry spills over into 2024

Antibody-drug conjugates, one of the creams of the crop in 2023 biopharma dealmaking, are riding into 2024 on a strong note as Roche pays $50 million upfront to collaborate with a biotech in China, where many of the ADC deals have been made recently.

The Swiss Big Pharma is pairing up with Suzhou-based MediLink Therapeutics, which teamed with BioNTech last fall for $70 million upfront and with Zai Lab last April for an undisclosed amount.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Novartis shareholders vote in favor of Sandoz spinoff, separation set for early October

Novartis’ Sandoz spinoff is right on track following a shareholder vote in favor of a full separation on Friday. The generics and biosimilars unit is

September 16, 2023

Pα+ Psychedelic Bulletin #157: Psilocybin for Generalised Anxiety Disorder; Uptick in Psilocybin-Related Poison Centre Calls – Psychedelic Alpha

Featured content in this Issue: Incannex Shares Topline Results from Phase 2a Study of Psilocybin for Generalised Anxiety Disorder An Uptick in Psilocybin-Related Poison Centre

March 1, 2024

Pharmalittle: We’re reading about a deal for a Moderna bird flu shot, NIH trial shortcomings, and more

Rise and shine, everyone, another busy day is on the way. We can tell because countless birds are chirping outside our window, the pace of

May 30, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.